CELTAXSYS, INC.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2004-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.celtaxsys.com
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Acebilustat (CTX-4430)
- Conditions
- Heathy Volunteers
- Interventions
- Drug: [14C]-acebilustat solution
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Celtaxsys, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03964558
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients
- First Posted Date
- 2015-05-14
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Celtaxsys, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT02443688
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Providence Health and Services, Anchorage, Alaska, United States
🇺🇸Banner University of Arizona Medical Center, Tucson, Arizona, United States
CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2016-08-02
- Lead Sponsor
- Celtaxsys, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT02385760
- Locations
- 🇦🇺
Clinical Trials Woden Dermatology, Phillip, Australian Capital Territory, Australia
🇦🇺St George Dermatology, Kogarah, New South Wales, Australia
🇦🇺Central Sydney Dermatology, Sydney, New South Wales, Australia
Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of CTX 4430 and Midazolam
- First Posted Date
- 2014-09-08
- Last Posted Date
- 2014-10-10
- Lead Sponsor
- Celtaxsys, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02233244
- Locations
- 🇬🇧
Celerion, Belfast, United Kingdom
Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 in Cystic Fibrosis Patients
- First Posted Date
- 2013-09-18
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Celtaxsys, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT01944735
- Locations
- 🇬🇧
The Medicinces Evaluation Unit, Wythenshawe, Manchester, United Kingdom
🇬🇧Celerion, Belfast, Northern Ireland, United Kingdom
🇬🇧Glasgow Clinical Research Facility, Glasgow, United Kingdom
- Prev
- 1
- 2
- Next